Sign Up

GREY WOLF ANIMAL HEALTH REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

TORONTO, Aug. 25, 2025 /CNW/ - Grey Wolf Animal Health Corp. (TSXV:WOLF) ("Grey Wolf" or the "Company"), a Canadian diversified health company, today announced financial results for the three- and six- months ended June 30, 2025. All results are reported in Canadian dollars.

Highlights

Revenue for the quarter increased year over year by 32.3% to $9.5 million. Revenue increased by 31.7% to $17.4 million for the first six months of the year.

Gross profit increased year over year by 40.6% to $5.3 million for the quarter and 37.6% to $9.5 million for the first six months of the year.

Adjusted EBITDA1 increased year over year by 56.8% to $2.2 million for the quarter and 53.2% to $3.4 million for the first six months of the year.

"Q2 2025 represented our strongest historical quarter for both revenue and Adjusted EBITDA1", said Angela Cechetto, Chief Executive Officer. "Our Pharmacy business continues to perform well with sales up year-over-year by 51.4% to $6.2 million and 57.8% to $11.3 million respectively, in the quarter and year-to-date.  This growth is driven by an increase in sales of compounded products and the impact of the acquisition of the Compounding Pharmacy of Manitoba (CPM) in December 2024.  Excluding the impact of CPM, our pharmacy business continues to grow organically at 10.6% year to date."

Ms. Cechetto went on to say, "our Animal Health business was up 7.6% in the second quarter and relatively flat year to date over the prior year periods. While we saw a slight uptick, particularly in sales of our gastrointestinal and behavior products during the spring season overall, there continues to be softness in visits to veterinary clinics. Adjusted EBITDA1 increased by 53.2% year to date as a result of higher revenue and gross margins, with our Adjusted EBITDA1 margin improving to 19.6% year to date vs 16.9% in the prior year."

Key Financial Data and Comparative Results

Three months ended

Six months ended

Jun 30, 2025

Jun 30, 2024

Jun 30, 2025

Jun 30, 2024

Revenue

$9,523,600

$7,197,074

$17,445,435

$13,243,579

Gross profit

5,312,293

3,778,131

9,482,005

6,890,290

Gross profit %

55.8 %

52.5 %

54.4 %

52.0 %

Total operating expenses

3,833,453

2,774,697

7,481,966

5,595,707

Operating income for the period

1,478,840

1,003,434

2,000,039

1,294,583

Income tax expense (recovery)

306,954

325,699

360,109

379,470

Net income for the period

751,230

577,547

778,478

703,619

Earnings per share

Basic and diluted

$0.02

$0.02

$0.02

$0.02

EBITDA

2,153,686